New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
15:28 EDTNSPHNanosphere receives FDA clearance for C. difficile test
Nanosphere announced the FDA granted 510(k) clearance permitting marketing of its C.difficile test on the automated sample-to-result Verigene System. The C. difficile test expands Nanosphere's infectious disease test capabilities. C. difficile infection is a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death. In less than two hours, the C. difficile test detects the toxin A and B gene sequences of C. difficile and identifies the PCR ribotype 027 strain which is associated with increased severity of disease and used for infection control. Early and accurate diagnosis of C. difficile infections is critical in both the proper treatment of infected patients and subsequent implementation of isolation and containment procedures to prevent further spread of the infection.
News For NSPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2014
09:21 EDTNSPHOn The Fly: Pre-market Movers
Subscribe for More Information
08:09 EDTNSPHNanosphere reports FDA clearance for Verigene EP Nucleic Acid Test
Nanosphere announced it has received 510(k) clearance from the FDA for its Verigene Enteric Pathogens Nucleic Acid Test, or EP, which now includes additional viral targets, as well as the bacterial and toxigenic targets cleared by FDA earlier this summer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use